- India
- /
- Medical Equipment
- /
- NSEI:NURECA
Nureca Second Quarter 2025 Earnings: ₹0.48 loss per share (vs ₹2.90 profit in 2Q 2024)
Nureca (NSE:NURECA) Second Quarter 2025 Results
Key Financial Results
- Revenue: ₹343.6m (up 9.6% from 2Q 2024).
- Net loss: ₹4.82m (down by 117% from ₹28.9m profit in 2Q 2024).
- ₹0.48 loss per share (down from ₹2.90 profit in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nureca shares are down 9.1% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for Nureca you should be aware of, and 1 of them is concerning.
Valuation is complex, but we're here to simplify it.
Discover if Nureca might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:NURECA
Excellent balance sheet low.